AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
The current AbbVie(ABBV) stock price is $251.35, with a market capitalization of 444.15B. The stock trades at a price-to-earnings (P/E) ratio of 125.43 and offers a dividend yield of 2.65%.
On 2026-06-30, AbbVie(ABBV) stock traded between a low of $250.10 and a high of $255.50. Shares are currently priced at $251.35, which is +0.5% above the low and -1.6% below the high.
AbbVie(ABBV) shares are trading with a volume of 7M, against a daily average of 12.37M.
During the past year, AbbVie(ABBV) stock moved between $181.75 at its lowest and $255.99 at its peak.
During the past year, AbbVie(ABBV) stock moved between $181.75 at its lowest and $255.99 at its peak.
ABBV News
Key Points AbbVie recently announced an acquisition that may help it remain a leader in immunology. Between AbbVie's strong lineup, deep pipeline, and dividen...
A bipartisan group of U.S. lawmakers has opened national security investigations into whether drugmakers Merck (MRK) and AbbVie (ABBV) have been involved in cli...
(RTTNews) - Nxera Pharma Co., Ltd. (SOLTF) on Tuesday said it received a $10 million milestone payment from AbbVie (ABBV) after achieving a fourth R&D milestone...
Analyst ratings
75%
of 32 ratingsMore ABBV News
Genmab's logo on its Copenhagen office. Genmab, AbbVie said they would discuss next steps with regulators. Joost Melis Genmab GMAB 6.87 %increase; up pointing...
AbbVie (ABBV) has just reported a cluster of regulatory milestones, including positive European opinions for Rinvoq in severe alopecia areata and non segmental...
AbbVie (ABBV) announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab, a T-cell engaging bispecific antibody,...
A new 55 mg pre-filled syringe (PFS) has also been approved to support weight-based dosing for patients weighing less than 40 kg, while the currently available...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more conf...
When a stock hits a new 52-week high, it can be a sign that things are going well for the business and that investors are recognizing some encouraging value. Ho...
AbbVie (ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, has adopted an opinion recommending the ap...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.